Literature DB >> 15894477

Severity distribution of chronic obstructive pulmonary disease (COPD) in Dutch general practice.

Martine Hoogendoorn1, Talitha L Feenstra, Tjard R J Schermer, Arlette E Hesselink, Maureen P M H Rutten-van Mölken.   

Abstract

The actual burden of chronic obstructive pulmonary disease (COPD) in terms of health care use and costs strongly depends on the distribution of disease severity. For the Netherlands, the distribution of diagnosed COPD was estimated by classifying all patients with a physician diagnosis of COPD from two different sources of general practitioners (GP)-data into mild (27%), moderate (55%), severe (15%) or very severe COPD (3%) based on their post-bronchodilator FEV1% predicted, according to the GOLD-guidelines. This distribution will most likely shift to the less severe stages when under-reporting and under-diagnosis are reduced.

Entities:  

Mesh:

Year:  2006        PMID: 15894477     DOI: 10.1016/j.rmed.2005.04.004

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

1.  Chronic obstructive pulmonary disease is not a risk factor for polyneuropathy: A prospective controlled study.

Authors:  Nora A Visser; Nicolette C Notermans; Ferdinand Teding van Berkhout; Leonard H van den Berg; Alexander Fje Vrancken
Journal:  Chron Respir Dis       Date:  2016-03-15       Impact factor: 2.444

2.  Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe.

Authors:  Paul W Jones; Guy Brusselle; Roberto W Dal Negro; Montse Ferrer; Peter Kardos; Mark L Levy; Thierry Perez; Juan José Soler Cataluña; Thys van der Molen; Lukasz Adamek; Norbert Banik
Journal:  Prim Care Respir J       Date:  2012-09

3.  The validity of diagnostic support of an asthma/COPD service in primary care.

Authors:  Annelies Lucas; Frank Smeenk; Ivo Smeele; Tim Brouwer; Onno van Schayck
Journal:  Br J Gen Pract       Date:  2007-11       Impact factor: 5.386

4.  Lung function decline in relation to diagnostic criteria for airflow obstruction in respiratory symptomatic subjects.

Authors:  Reinier P Akkermans; Marvin A Berrevoets; Ivo J Smeele; Annelies E Lucas; Bart P Thoonen; Joke G Grootens-Stekelenburg; Yvonne F Heijdra; Chris van Weel; Tjard R Schermer
Journal:  BMC Pulm Med       Date:  2012-03-22       Impact factor: 3.317

Review 5.  Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.

Authors:  Kokuvi Atsou; Christos Chouaid; Gilles Hejblum
Journal:  BMC Med       Date:  2011-01-18       Impact factor: 8.775

Review 6.  Association between lung function and exacerbation frequency in patients with COPD.

Authors:  Martine Hoogendoorn; Talitha L Feenstra; Rudolf T Hoogenveen; Maiwenn Al; Maureen Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-12-09

7.  A method to study the effect of bronchodilators on smoke retention in COPD patients: study protocol for a randomized controlled trial.

Authors:  W D van Dijk; P T J Scheepers; R Cremers; J W M Lenders; W Klerx; C van Weel; T R J Schermer; Y Heijdra
Journal:  Trials       Date:  2011-02-10       Impact factor: 2.279

8.  Adjusting for COPD severity in database research: developing and validating an algorithm.

Authors:  Lucas M A Goossens; Christine L Baker; Brigitta U Monz; Kelly H Zou; Maureen P M H Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-12-06

9.  Systemic impairment in relation to disease burden in patients with moderate COPD eligible for a lifestyle program. Findings from the INTERCOM trial.

Authors:  Carel R van Wetering; Floortje E van Nooten; Stijn J M Mol; Martine Hoogendoorn; Maureen P M H Rutten-Van Mölken; Annemie M Schols
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

10.  A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.

Authors:  Petra Menn; Reiner Leidl; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.